Michael A Metzger Syndax Pharmaceuticals Inc (SNDX) insider trading activity

Michael A Metzger is Chief Executive Officer of Syndax Pharmaceuticals Inc. Currently has a direct ownership of 163,909 shares of SNDX, which is worth approximately $2.61 Million. The most recent transaction as insider was on Feb 07, 2024, when has been sold 146,250 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 164K

0% 3M change

828.19% 12M change

Total Value Held $2.61 Million

Michael A Metzger Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 07 2024	BUY Grant, award, or other acquisition	-	146,250 Added 47.15%	163,909 Common Stock
Feb 06 2023	SELL Open market or private sale	$164,706 $27.64 p/Share	5,959 Reduced 25.23%	17,659 Common Stock
Feb 06 2023	BUY Exercise of conversion of derivative security	$38,018 $6.38 p/Share	5,959 Added 20.15%	23,618 Common Stock
Oct 06 2022	SELL Open market or private sale	$410,482 $25.29 p/Share	16,231 Reduced 47.89%	17,659 Common Stock
Oct 06 2022	BUY Exercise of conversion of derivative security	$142,346 $8.77 p/Share	16,231 Added 32.38%	33,890 Common Stock
Oct 04 2022	SELL Open market or private sale	$32,026 $25.02 p/Share	1,280 Reduced 6.76%	17,659 Common Stock
Oct 04 2022	BUY Exercise of conversion of derivative security	$11,226 $8.77 p/Share	1,280 Added 6.33%	18,939 Common Stock
Oct 03 2022	SELL Open market or private sale	$72,104 $25.01 p/Share	2,883 Reduced 14.03%	17,659 Common Stock
Oct 03 2022	BUY Exercise of conversion of derivative security	$25,284 $8.77 p/Share	2,883 Added 12.31%	20,542 Common Stock
Sep 30 2022	SELL Open market or private sale	$740,742 $25.02 p/Share	29,606 Reduced 62.64%	17,659 Common Stock
Sep 30 2022	BUY Exercise of conversion of derivative security	$259,645 $8.77 p/Share	29,606 Added 38.51%	47,265 Common Stock
Jul 25 2022	SELL Open market or private sale	$665,538 $21.06 p/Share	31,602 Reduced 64.15%	17,659 Common Stock
Jul 25 2022	BUY Exercise of conversion of derivative security	$201,621 $6.38 p/Share	31,602 Added 51.72%	29,497 Common Stock
Jul 07 2022	SELL Open market or private sale	$2,100 $21.0 p/Share	100 Reduced 0.56%	17,659 Common Stock
Jul 07 2022	BUY Exercise of conversion of derivative security	$638 $6.38 p/Share	100 Added 0.56%	17,759 Common Stock
Jul 06 2022	SELL Open market or private sale	$316,240 $21.07 p/Share	15,009 Reduced 45.94%	17,659 Common Stock
Jul 06 2022	BUY Exercise of conversion of derivative security	$95,757 $6.38 p/Share	15,009 Added 31.48%	32,668 Common Stock
Dec 20 2021	SELL Open market or private sale	$1,237,690 $20.29 p/Share	61,000 Reduced 77.55%	17,659 Common Stock
Dec 20 2021	BUY Exercise of conversion of derivative security	$462,380 $7.58 p/Share	61,000 Added 49.33%	62,659 Common Stock
Dec 17 2021	SELL Open market or private sale	$31,878 $19.02 p/Share	1,676 Reduced 8.67%	17,659 Common Stock
Dec 17 2021	BUY Exercise of conversion of derivative security	$10,693 $6.38 p/Share	1,676 Added 7.98%	19,335 Common Stock
Dec 16 2021	SELL Open market or private sale	$433,402 $19.08 p/Share	22,715 Reduced 56.26%	17,659 Common Stock
Dec 16 2021	BUY Exercise of conversion of derivative security	$144,922 $6.38 p/Share	22,715 Added 36.0%	40,374 Common Stock
Dec 13 2021	SELL Open market or private sale	$697,401 $19.05 p/Share	36,609 Reduced 67.46%	17,659 Common Stock
Dec 13 2021	BUY Exercise of conversion of derivative security	$248,575 $6.79 p/Share	36,609 Added 41.21%	52,223 Common Stock

Also insider at

CTIC

CTI BIOPHARMA CORP Healthcare

Director

PYXS

Pyxis Oncology, Inc. Healthcare

MAM